Canadian company reports progress on COVID vaccine

iStock-1218961180

Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.
    
The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.
    
Medicago says the side effects were generally mild to moderate and short in duration.
    
The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.
    
Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.
    
The federal government has signed a $173-million contract with Medicago to secure the rights to buy 76 million doses of its vaccine, should it meet health and safety standards.

  • PARENTAL GUIDANCE - Episode 47

    This week Chrissy Sadowski talks to Joe Kargiannakis to about the importance of you and your partner being on the same team when it comes to discipline.
  • LIFE UNSCRIPTED - Episode 39

    Premiers, mayors and even medical officers of health are becoming household names as each day they're in front of a microphone talking about their response to the pandemic.  But what's it like being responsible in smaller communities where mayors, city and regional staff are working to keep services running. This week on Life Unscripted Janice Arnoldi talks to St. Catharines Mayor Walter Sendzik about what's changed because of the pandemic and how city staff, many of whom are an essential service, are coping with the stress.
  • LIZ FLEMING TRAVELS - November 28th

    This week on Liz Fleming Travels, Liz is joined by Daniela Escobar from CAA Travel to talk about insurance for travelers. What does it cover and when? She also talks about great train trips in Canada and the things we'd never travel without.